In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
How to Find a Cancer Treatment Trial
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
Featured Clinical Trials Supported by NCI

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 1139 for your search:

Drug:  paclitaxel
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer

Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML18527, NCT00121836

Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC)

Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 97-02-12, NCT00686322

A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Patients With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML25288, NCT01301729

Phase II/III Randomized Study of a New Paclitaxel Formulation Given by 3-Hour vs 96-Hour Infusion in Women with Refractory Metastatic Breast Cancer (Summary Last Modified 11/95)

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: any age
Sponsor: Other
Protocol IDs: MAOP-1195, NCI-V95-0749

Phase III Study of a 3-Hour Infusion of a New Paclitaxel Product in Refractory Ovarian Cancer, with a Phase II Crossover to a 96-Hour Infusion at Progression (Summary Last Modified 12/95)

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: MAOP-7195, NCI-V95-0750

Combination Chemotherapy in Treating Men With Germ Cell Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 16 to 50
Sponsor: Other
Protocol IDs: EORTC-30983, NCT00003643

Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000067047, SPRI-C/I98-102, SPRI-C98-102, NCI-V99-1544, NCT00003880

Phase II/III Randomized Trial of DOX vs TAX vs DOX/TAX/G-CSF in Patients with Metastatic Breast Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: any age
Sponsor: NCI
Protocol IDs: E-1193, NCCTG-923252, SWOG-9332, E-10292, E1193

Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: NBCG10, REK 378-04-03133, NMA 03-07568, NCT00201435

10.

A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA139-384, NCT00337532

11.

Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 40 to 75
Sponsor: Other
Protocol IDs: Hamamatsu 18-66, NCT00752115

12.

Paclitaxel and Carboplatin With or Without BMS-275291 in Treating Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: BR18, CAN-NCIC-BR18, BMS-CA161-003, CDR0000068153, NCT00006229

13.

Paclitaxel and Carboplatin With or Without Cediranib Maleate in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: BR24, CAN-NCIC-BR24, ZENECA-CAN-NCIC-BR24, FHCRC-6107, UWCC-UW 6107, UWCC- 06-2707-H/B, CDR0000450850, NCT00245154

14.

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02947, E4599, U10CA021115, CDR0000068744, ECOG-4599, CALGB-E4599, NCT00021060

15.

Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: UCL/09/105, Funder reference (academic), Funder reference (industry), 2009-017171-13, NCT01196741

16.

Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: GBG 66, 2011-000553-23, NCT01426880

17.

An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2007-001346-41, ISRCTN68510403, NCT00532194

18.

Phase III Randomized Study of G-CSF Priming Prior to Neoadjuvant TAX/CBDCA Followed by a Phase I Dose-Seeking Study of TAX/CBDCA During Definitive Radical Thoracic Irradiation for Stages IIIB/Bulky IIIA Nonsmall Cell Lung Cancer (Summary Last Modified 12/95)

Phase: Phase III, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: FCCC-94001, NCI-V94-0479

19.

Phase III Randomized Study of High-Dose Paclitaxel Administered as a 3-Hour vs a 24-Hour Infusion in Women with Metastatic or Locally Advanced Breast Cancer (Summary Last Modified 11/2000)

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NSABP-B-26

20.

Phase III Randomized Study of Paclitaxel Administered as a 3-Hour Infusion at Three Different Doses in Women with Recurrent Advanced Breast Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CLB-9342, CALGB-9342

21.

Phase III Randomized Study of Adjuvant CA (Cyclophosphamide/Doxorubicin) Comparing Standard- vs Intermediate- vs High-Dose Doxorubicin, with vs without Subsequent Paclitaxel, in Women with Node-Positive Breast Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: over 18
Sponsor: NCI
Protocol IDs: CLB-9344, E-C9344, NCCTG-943051, SWOG-9410, INT-0148

22.

Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: Any age
Sponsor: NCI, Other
Protocol IDs: CDR0000063600, GOG-152, GOG-0152, NCT00002568

23.

Phase III Randomized Study of TAX/CDDP vs CTX/CDDP in Patients with Advanced Epithelial Ovarian Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: EORTC-55931, CAN-NCIC-OV10, SCOTTISH-GYN-G42, SGCSG-NOCOVA-9410, OV10

24.

Phase III Randomized, Open-Label, Multicenter Study of Topotecan vs Paclitaxel as Single-Agent, Second-Line Therapy for Platinum-Refractory Advanced Epithelial Ovarian Carcinoma (Summary Last Modified 11/94)

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: SB-104864/039, NCI-V94-0490

25.

Phase III Randomized Study of Platinum Compound and Paclitaxel in Optimal Stage III Ovarian Epithelial Cancer: Cisplatin and Paclitaxel (24-Hour Continuous Infusion) vs Carboplatin and Paclitaxel (3-Hour Infusion)

Phase: Phase III
Type: Treatment
Status: Completed
Age: any age
Sponsor: NCI
Protocol IDs: GOG-0158, GOG-0158

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map